Skip to content

Cardio- and Renoprotective Effect of Remote Ischemic Preconditioning in Patients Undergoing Percutaneous Coronary Intervention

Cardio- and Reno-protective Effect of Remote Ischemic Preconditioning in Patients Undergoing Percutaneous Coronary Intervention. A Prospective, Non-randomized Controlled Trial.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02313441
Enrollment
200
Registered
2014-12-10
Start date
2013-09-30
Completion date
2014-12-31
Last updated
2019-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

remote ischemic preconditioning

Brief summary

Myocyte necrosis occurs frequently in elective percutanious percutaneous coronary intervention (PCI) and is associated with subsequent cardiovascular events. This study assessed the cardio- and reno-protective effect of remote ischemic preconditioning (RIPC) in patients undergoing elective PCI. 200 patients were randomized into 2 groups: 100 patients received RIPC (created by three 5-minute inflations of a blood pressure cuff to 200 mm Hg around the upper arm, separated by 5-minute intervals of reperfusion) \< 2 hours before the PCI procedure, and the control group (n = 100).

Interventions

The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patients between 18 and 85 years of age, * scheduled to undergo an elective PCI and * able to give an informed consent were eligible for enrollment in the study. * Elective PCI was defined as any coronary revascularization in a low-risk patient who presents to the facility for a planned PCI or for a coronary angiogram followed by ad hoc PCI.

Exclusion criteria

* (1) emergency PCI, (2) baseline troponin value ≥ 0.04 ng/mL, (3) nicorandil or glibenclamide use (preconditioning-mimetic and preconditioning-blocking medication, respectively), (4) those who could not give informed consent, and (5) patients with severe renal impairment or on regular dialysis.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of PCI- related myocardial infarction (MI 4a) at 24 hours after PCI.24 hoursPCI-related myocardial infarction (MI 4a) was defined as cardiac Troponin I (cTnI) elevation \>0.20ng/mL (5 times the upper reference limit) 24 hr. post PCI.

Secondary

MeasureTime frameDescription
incidence of contrast induced nephropathy (CIN) at 72 hours after contrast exposure72 hoursCIN was defined as an increase in the serum creatinine level of more than 0.5 mg/dl or more than 25 % from baseline within 3 days after procedure without any other identifiable cause of acute kidney injury.

Other

MeasureTime frameDescription
Chest pain severity during PCI1 hoursChest pain severity during PCI was graded on a scale of 0 for no pain to 10 for the most severe discomfort ever experienced
level of C-reactive protein (CRP)24 hr post PCI24h post procedureC-reactive protein level was measured 24 hr. post PCI to assess the inflammatory response .
major adverse events (MAE) at 3 month follow up90 days Follow-upDeath was defined as all-cause death at follow-up. Acute coronary syndrome (ACS) was defined using standard diagnostic criteria. Heart failure (HF) during follow-up, was defined as either the presence of rales in more than one third of the lung fields that did not clear with coughing or evidence of pulmonary oedema on chest radiograph. Hemodialysis as a complication of acute deterioration of renal function post PCI was also calculated. Only the most serious event of MAE was used to calculate the cumulative MAE per patient according to the following sequence: death\>ACS \> HF\> Hemodialysis.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026